Cencora Inc.

What does Cencora do?
Cencora distributes pharmaceutical products, including brand-name drugs, generic drugs, and specialty medications, to pharmacies, hospitals, physician offices, and other healthcare providers across the United States and internationally. The company also provides manufacturer services, patient support programs, specialty logistics, and veterinary pharmaceutical distribution through its subsidiaries.

Is Cencora publicly traded?
Yes, Cencora, Inc. trades on the New York Stock Exchange under ticker symbol COR. The company has no controlling shareholder, though Walgreens Boots Alliance holds approximately 15% of shares as the largest single investor.

What is Cencora's annual revenue?
In fiscal year 2024 (ended September 30, 2024), Cencora reported revenue of $294.0 billion, a 12.1% increase from the prior fiscal year. The company is one of the largest companies in the United States by revenue.

Why did AmerisourceBergen change its name to Cencora?
AmerisourceBergen changed its name to Cencora in August 2023 to reflect its evolution from a primarily domestic pharmaceutical distributor into a global healthcare solutions organization. The rebranding followed the 2021 acquisition of Alliance Healthcare, which significantly expanded the company's international operations, and was intended to signal the company's broader capabilities beyond traditional drug distribution.

Who is Cencora's CEO?
Robert P. Mauch became President and CEO of Cencora on October 1, 2024, succeeding Steven H. Collis, who had served as CEO since 2011. Collis transitioned to the role of Executive Chairman.

What is Cencora's role in the opioid settlement?
Cencora, along with McKesson and Cardinal Health, reached a $21 billion settlement with U.S. states and local governments in 2022 to resolve claims that the three distributors failed to adequately monitor suspicious opioid orders. Cencora's share of the settlement is approximately $6.1 billion, to be paid over 18 years.

Cencora traces its origins to two predecessor companies with deep roots in pharmaceutical distribution. AmeriSource Health Corporation was formed in 1985 through the merger of Alco Standard's pharmaceutical distribution business and other regional distributors. Bergen Brunswig Corporation had roots dating to the early 20th century, tracing its lineage to Bergen Drug Company, founded in 1888 in New Jersey.

The two companies merged in August 2001 to create AmerisourceBergen Corporation, combining their complementary geographic footprints and customer bases to create one of the three largest pharmaceutical distributors in the United States. The merger was valued at approximately $2.2 billion and created a company with annual revenues exceeding $40 billion at the time.

Throughout the 2000s, AmerisourceBergen expanded its capabilities beyond basic drug distribution into specialty pharmaceuticals, which require more complex handling, storage, and patient support services than traditional medications. The company built out its specialty distribution capabilities through acquisitions and organic investment, positioning itself to benefit from the rapid growth of high-cost specialty drugs.

In 2012, AmerisourceBergen formed a strategic partnership with Walgreens, under which Walgreens would source a significant portion of its pharmaceutical products through AmerisourceBergen. The partnership was later extended and deepened, with Walgreens Boots Alliance eventually acquiring approximately 15% of AmerisourceBergen's shares, making it the company's largest single shareholder.

The company expanded internationally through the acquisition of PharMerica's oncology business and, more significantly, through the 2021 acquisition of Alliance Healthcare, a European pharmaceutical distribution and services company, for approximately $6.5 billion. The Alliance Healthcare acquisition significantly expanded Cencora's international presence, adding operations in the United Kingdom, France, Germany, Spain, Portugal, and other European markets.

Steven H. Collis, who had served as CEO since 2011, announced a leadership transition in March 2024. Robert P. Mauch, who had served as Chief Operating Officer, became President and CEO on October 1, 2024, while Collis transitioned to Executive Chairman.

In August 2023, the company officially changed its name from AmerisourceBergen to Cencora, reflecting its transformation into a broader healthcare solutions organization with significant international operations and expanded service capabilities beyond traditional drug distribution.

Cencora has implemented comprehensive sustainability initiatives focused on environmental responsibility, ethical business practices, and healthcare accessibility across its pharmaceutical distribution operations. The company recognizes its critical role in the healthcare supply chain and is committed to reducing its environmental footprint while maintaining reliable service delivery to healthcare providers.

The company has invested in sustainable logistics and distribution operations, including energy-efficient distribution centers, electric vehicle fleet adoption, and optimized transportation routes to reduce greenhouse gas emissions. Cencora has implemented comprehensive waste reduction programs across its facilities, focusing on recycling, proper disposal of pharmaceutical waste, and reduction of packaging materials.

Cencora maintains strong environmental compliance programs for pharmaceutical storage and distribution, ensuring adherence to all regulatory requirements for temperature-controlled logistics and environmental protection. The company has implemented water conservation measures and renewable energy initiatives across its distribution network.

In ethical business practices, Cencora maintains comprehensive compliance programs for pharmaceutical distribution regulations, anti-corruption policies, and supply chain integrity. The company's sustainability reporting includes progress metrics on environmental initiatives, energy efficiency improvements, and waste reduction programs across its operations.

Cencora participates in industry sustainability initiatives and collaborates with pharmaceutical manufacturers to advance environmental performance across the healthcare supply chain. The company's ethical framework includes strong supplier responsibility programs and community engagement activities focused on healthcare education and access.

Cencora has received recognition for its operational excellence, workplace culture, and industry leadership in healthcare distribution:

• Fortune 500 Ranking: Consistent ranking among the largest companies in the United States by revenue
• Great Place to Work: Multiple years of certification for workplace culture and employee satisfaction
• Healthcare Industry Awards: Recognition for excellence in pharmaceutical distribution and healthcare services
• Supply Chain Excellence: Recognition for logistics management and distribution efficiency
• Diversity & Inclusion Awards: Recognition for workplace diversity and inclusion programs
• Environmental Leadership: Recognition for sustainability initiatives and environmental stewardship
• Healthcare Technology Awards: Recognition for innovation in healthcare technology and digital solutions
• Community Engagement: Recognition for corporate social responsibility and community involvement

These awards reflect Cencora's commitment to operational excellence, employee satisfaction, and responsible business practices while maintaining its position as a leading healthcare distribution company.

Cencora's most significant legal matter is its participation in the $21 billion opioid settlement reached in 2022 with U.S. states and local governments. The settlement resolved claims that Cencora (then AmerisourceBergen), McKesson, and Cardinal Health failed to adequately monitor and report suspicious orders of opioid medications, contributing to the opioid epidemic that has caused hundreds of thousands of deaths in the United States. Cencora's share of the settlement is approximately $6.1 billion paid over 18 years.

The company has also faced scrutiny over its relationship with Walgreens Boots Alliance, its largest customer and significant shareholder. Regulators and investors have examined whether the commercial relationship between the two companies creates conflicts of interest in pricing and contract negotiations.